MRI manifestions correlate with survival of glioblastoma multiforme patients

Cancer Biology and Medicine

Volumn 9, Issue 2, 2012, Pages 120-123

  Li, Wen Bin ^a   Tang, Kai ^b   Chen, Qian ^b   Li, Shuai ^c   Qiu, Xiao Guang ^b   Li, Shao Wu ^b   Jiang, Tao ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY   (China)

Author keywords

Diffusion magnetic resonance imaging; Glioblastoma multiforme; Survival

Indexed keywords

TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; EDEMA; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; SURVIVAL RATE; SURVIVAL TIME;

EID: 84876307416     PISSN: 20953941     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.2095-3941.2012.02.007     Document Type: Article

References (16)

1. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol 2005; 109: 93-108.
2. Kowalczuk A, Macdonald RL, Amidei C, et al. Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 1997; 41: 1028-1036.
3. Stupp R, Mason WP, Van Den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
4. Lacroix M, Abi-Said D, Fourney DR et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-198.
5. Laws ER, Parney IF, Huang W et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: Data from the Glioma Outcomes Project. J Neurosurg 2003; 99: 467-473.
6. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
7. Helseth R, Helseth E, Johannesen TB, et al, Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand 2010; 122: 159-167.
8. Ryken TC, Frankel B, Julien T, Olson JJ. Surgical management of newly diagnosed glioblastoma in adults: Role of cytoreductive surgery. J Neurooncol 2008; 89: 271-286.
9. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
10. Rogne SG, Konglund A, Meling TR et al. Intracranial tumor surgery in patients >70 years of age: Is clinical practice worthwhile or futile? Acta Neurol Scand 2009; 120: 288-294.
11. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: Prognosis, extent of resection, and survival. J Neurosurg 2001; 95: 190-198.
12. Stark AM, Nabavi A, Mehdorn HM, Blomer, U. Glioblastoma multiforme: Report of 267 cases treated at a single institution. Surg Neurol 2005; 63: 162-169.
13. Kleihues P, Burger PC, Aldape KD et al. Glioblastoma. In: Louis D et al., eds. WHO classification of tumours of the central nervous system. Lyon: IARC Press, 2007; 72-73.
14. Li WB, Tang K, Zhang W, et al. Relationship between magnetic resonance imaging and molecular pathology in patients with glioblastoma multiforme. Chin Med J (Engl) 2011; 124: 2589-2592.
15. Martinez R, Rohde V, and Schackert G. Different molecular patterns in glioblastoma multiforme subtypes upon recurrence. J Neurooncol 2010; 96: 321-329.
16. Diehn M, Nardini C, Wang DS, et al, Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. PNAS 2008; 105: 5213-5218.